Incyte's vision is to become a leading drug discovery and development company by building a proprietary product pipeline of novel small molecule drugs. We have an experienced management and discovery team. Our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference in healthcare, improve the lives of patients and build significant sustainable value for our shareholders.
We have assembled a competitive and talented drug discovery and development team, which has extensive experience in a number of therapeutic areas. We have active internal drug discovery programs focused on the identification of novel small molecule drugs for oncology, inflammation, HIV and diabetes.
Dr. Jeffrey Dick
In this interview conducted at Pittcon 2023 in Philadelphia, Pennsylvania, we spoke to Dr. Jeffrey Dick about his work studying the chemistry of small volumes and nano-electrochemical tools.
Here, AZoNano speaks with Dirigent Acoustics about the benefits graphene could bring to acoustic and audio technologies and how the company's relationship with the Graphene Flagship has shaped its success.
In this interview, KLA's Bryan Crawford explains everything there is to know about nanoindentation, the challenges that the field currently faces, and how they can be overcome.
The Diamond Interaction Chamber (DIXC) is integral to the NanoGenizer high-pressure homogenizer.
The new AUTOsample-100 mounting autosampler is compatible with the 100 MHz benchtop NMR spectrometer.
The Vistec SB3050-2 is the most advanced electron beam lithography system with variable-shaped beam technology, allowing a wide range of applications in research and development, prototyping, and small-volume production.